CoChat

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality

Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., Mannucci, E. · 2007 · Diabetes/Metabolism Research and Reviews
Cited by 109

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Aim of the present study is the comparison of all‐cause, cardiovascular and non‐cardiovascular mortality, and cardiac morbidity, between patients treated with glibenclamide and gliclazide. Methods: A retrospective observational cohort study was performed on a consecutive series of 568 outpatients (282 women, 286 men) with type 2 diabetes treated with either glibenclamide (n = 378) or gliclazide (n = 190). Information on all‐cause mortality and on causes of death up to 31 December 2004 was obtained by the City of Florence Registry Office. Non‐fatal cases requiring hospitalization were identified through the regional hospital discharge system using International Classification of Diseases. Results: Mean follow‐up was 5.0 ± 1.6 and 4.4 ± 2.0 years for death and cardiac events, respectively; during follow‐up, 33 and 11 deaths were observed in the glibenclamide and gliclazide groups, with a yearly mortality rate of 4.3 and 2.2%, respectively (p < 0.05). At Cox regression, after adjustment for potential confounders, including comorbidity, glibenclamide treatment was associated with a significant increase in all‐cause mortality [OR 2.1(1.2;2.7), p < 0.05], while the difference in cardiovascular mortality was not statistically significant after adjustment for age and sex. Mortality for malignancies was significantly higher in patients treated with glibenclamide after adjustment for age, sex, BMI, and insulin and metformin treatment, [OR 3.6(1.1;11.9); p < 0.05]. A higher incidence of cardiac events was associated with glibenclamide treatment only in patients with previously known ischaemic heart disease. Conclusions: Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide. Copyright © 2007 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.736

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 109

Metadata

Authors
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2007-03-23
Volume
23
Issue
6
Pages
479-484
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1965111919
Cited by
109
References
9
FWCI
5.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality. https://app.cochat.ai/papers/10.1002/dmrr.736
The paper
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007). Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.736

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.